Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Gland Pharma receives USFDA approval for Angiotensin II Acetate injection
Gland Pharma secures 180-day exclusivity for Angiotensin II Acetate Injection following USFDA approval
IGI reports phase 1 results of ISB 2001 trispecific antibody in relapsed or refractory multiple…
TRIgnite-1 study shows 79 per cent response rate and no dose-limiting toxicities in early-stage trial of BCMA × CD38 × CD3…
Sun Pharma ends development of SCD-044 after phase 2 trials fail to meet primary endpoints
SCD-044 trials for psoriasis and atopic dermatitis show no major safety concerns
Zydus Lifesciences acquires Agenus Biologics facilities in US, enters global CDMO market
Company also signs licensing deal for exclusive rights to immuno-oncology therapies Botensilimab and Balstilimab in India and Sri…
India’s pharma startups raise $254.7 million in May 2025: Tracxn
Seed-stage deals dominate as funding surges over fivefold from April, led by PB Healthcare’s $156 million round
TDB backs Nitika Pharmaceutical Specialties for domestic production of complex excipients
DST’s Technology Development Board extends financial support to Nagpur-based Nitika for manufacturing 14 advanced excipients under…
Indoco launches Ticagrelor film-coated tablets 90mg in the UK market
Indoco Remedies UK begins distribution of cardiovascular treatment via Clarity Pharma across the United Kingdom
Oliver Wyman appoints Dr Chirag Adatia as partner to lead health, life sciences in India
Dr Adatia to support Oliver Wyman’s healthcare and investor-focused strategy in India with cross-sector experience and digital…
Cipla appoints Prabhakaran Nair as Global Chief Manufacturing Officer
Nair to take charge from July 1, 2025; joins Cipla’s senior management with focus on global manufacturing and compliance
What US FDA’s new surprise foreign inspections plan means for India
Pharma companies exporting to the US should now rightly be on guard and start preparing for the inevitable “knock on the factory…